公开(公告)号：US11161844B2

公开(公告)日：2021-11-02

申请号：US16492554

申请日：2018-03-01

申请人： Pfizer Inc.

发明人： Thomas Allen Chappie ,  Paul Galatsis ,  Michelle Renee Garnsey ,  Christopher John Helal ,  Jaclyn Louise Henderson ,  Bethany Lyn Kormos ,  Ravi G. Kurumbail ,  Luis Angel Martinez-Alsina ,  Martin Youngjin Pettersson ,  Antonia Friederike Stepan ,  Travis T. Wager

IPC分类号： C07D471/04 ,  C07D471/14

摘要： The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof; wherein R1, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

公开(公告)号：US11111242B2

公开(公告)日：2021-09-07

申请号：US15446500

申请日：2017-03-01

申请人： Pfizer Inc.

发明人： Atli Thorarensen ,  Matthew Frank Brown ,  Agustin Casimiro-Garcia ,  Ye Che ,  Jotham Wadsworth Coe ,  Mark Edward Flanagan ,  Adam Matthew Gilbert ,  Matthew Merrill Hayward ,  Jonathan David Langille ,  Justin Ian Montgomery ,  Jean-Baptiste Telliez ,  Rayomand Jal Unwalla ,  John I. Trujillo

IPC分类号： A61K31/4523 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/10 ,  C07D498/04

摘要： The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylam ides and analogues thereof, having the structure: or a pharmaceutically acceptable salt thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

公开(公告)号：US20210268095A1

公开(公告)日：2021-09-02

申请号：US17180959

申请日：2021-02-22

申请人： Pfizer Inc.

发明人： Robert G.K. Donald ,  Rosalind Pan

IPC分类号： A61K39/108 ,  A61K39/385 ,  A61P31/04 ,  A61P37/04

摘要： This invention provides a polypeptide derived from E. coli or a fragment thereof, including compositions and methods thereof. In one embodiment, the compositions comprise a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides or conjugates thereof. In a further aspect, the compositions further comprise modified O-polysaccharide molecules derived from Klebsiella pneumoniae or conjugates thereof.

公开(公告)号：US20210261530A1

公开(公告)日：2021-08-26

申请号：US17235836

申请日：2021-04-20

申请人： Pfizer Inc.

发明人： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC分类号： C07D403/12 ,  A61P35/00 ,  C07D413/12

摘要： This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20210246213A1

公开(公告)日：2021-08-12

申请号：US17154588

申请日：2021-01-21

申请人： Pfizer Inc.

发明人： James Reasoner Apgar ,  Sheryl Rubio Bowley ,  Joanne Elizabeth-Ayriss Elwell ,  Laura Lin ,  Jatin Narula ,  Chuenlei Parng ,  Debra Denene Pittman ,  Swapnil Rakhe ,  Chihyi Vincent Yu

IPC分类号： C07K16/28

摘要： The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin. The invention includes uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

公开(公告)号：US11066481B2

公开(公告)日：2021-07-20

申请号：US15746305

申请日：2016-07-22

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  PFIZER INC.

发明人： Thomas Mikita ,  Lauren K. Ely ,  Huilan Gao ,  Yun Kim ,  Isaac J. Rondon ,  Tovo David ,  Shaun R. Coughlin

IPC分类号： C07K16/36

摘要： In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.

公开(公告)号：US20210214414A1

公开(公告)日：2021-07-15

申请号：US17125903

申请日：2020-12-17

申请人： Pfizer Inc. ,  Boston Medical Center Corporation

发明人： Stephen Berasi ,  Janet Elizabeth Buhlmann ,  Nathan Higginson-Scott ,  Michael Shamashkin ,  Matthew Russo ,  Stefano V. Gulla ,  Zong Sean Juo ,  Sreekumar R. Kodangattil ,  Weining Lu ,  Xueping Fan ,  David J. Salant

IPC分类号： C07K14/705 ,  C12N15/11 ,  C12N15/52 ,  C12N15/09 ,  C07K19/00 ,  C12N15/63 ,  C07H21/04 ,  A61K38/17 ,  A61P13/12

摘要： The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.

公开(公告)号：US11059876B2

公开(公告)日：2021-07-13

申请号：US16286158

申请日：2019-02-26

申请人： Pfizer Inc.

发明人： Yik Andy Yeung ,  Reid Martin Renny Feldman ,  Ling Hon Matthew Chu ,  Javier Fernando Chaparro Riggers ,  Ivana Djuretic ,  Laura Lin ,  Lidia Mosyak

IPC分类号： C07K14/54 ,  A61K39/395 ,  A61K38/17 ,  A61K38/20 ,  A61K35/17 ,  C07K19/00 ,  A61P35/00 ,  C07K16/32 ,  C07K16/28 ,  C07K14/55 ,  C12N15/62 ,  A61K38/19 ,  A61K45/06

摘要： The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.

公开(公告)号：US20210163455A1

公开(公告)日：2021-06-03

申请号：US17171385

申请日：2021-02-09

申请人： Pfizer Inc.

发明人： Gary Erik Aspnes ,  Scott W. Bagley ,  John M. Curto ,  David James Edmonds ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David A. Griffith ,  Kim Huard ,  Yajing Lian ,  Chris Limberakis ,  Allyn T. Londregan ,  Alan M. Mathiowetz ,  David W. Piotrowski ,  Roger B. Ruggeri

IPC分类号： C07D405/12 ,  C07C53/06 ,  C07C53/10 ,  C07C215/40 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04

摘要： Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US20210145957A1

公开(公告)日：2021-05-20

申请号：US17161119

申请日：2021-01-28

申请人： Pfizer Inc.

发明人： Annaliesa Sybil Anderson ,  Amardeep Singh Bhupender Bhalla ,  Robert G.K. Donald ,  Jianxin Gu ,  Kathrin Ute Jansen ,  Rajesh Kumar Kainthan ,  Lakshmi Khandke ,  Jin-Hwan Kim ,  Paul Liberator ,  Avvari Krishna Prasad ,  Mark Edward Ruppen ,  Ingrid Lea Scully ,  Suddham Singh ,  Cindy Xudong Yang

IPC分类号： A61K39/09 ,  C07K16/12 ,  C07K16/44 ,  A61K39/39 ,  A61K39/40 ,  A61K47/10 ,  A61K47/26

摘要： The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B. streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.